Customizing G Protein-coupled receptor models for structure-based virtual screening.

This review will focus on the construction, refinement, and validation of G Protein-coupled receptor models for the purpose of structure-based virtual screening. Practical tips and tricks derived from concrete modeling and virtual screening exercises to overcome the problems and pitfalls associated with the different steps of the receptor modeling workflow will be presented. These examples will not only include rhodopsin-like (class A), but also secretine-like (class B), and glutamate-like (class C) receptors. In addition, the review will present a careful comparative analysis of current crystal structures and their implication on homology modeling. The following themes will be discussed: i) the use of experimental anchors in guiding the modeling procedure; ii) amino acid sequence alignments; iii) ligand binding mode accommodation and binding cavity expansion; iv) proline-induced kinks in transmembrane helices; v) binding mode prediction and virtual screening by receptor-ligand interaction fingerprint scoring; vi) extracellular loop modeling; vii) virtual filtering schemes. Finally, an overview of several successful structure-based screening shows that receptor models, despite structural inaccuracies, can be efficiently used to find novel ligands.

[1]  D. Rognan,et al.  Selective structure-based virtual screening for full and partial agonists of the beta2 adrenergic receptor. , 2008, Journal of medicinal chemistry.

[2]  Didier Rognan,et al.  Positive and Negative Allosteric Modulators of the Ca2+-sensing Receptor Interact within Overlapping but Not Identical Binding Sites in the Transmembrane Domain* , 2004, Journal of Biological Chemistry.

[3]  R. Wong,et al.  Comparison of the Potential Multiple Binding Modes of Bicyclam, Monocylam, and Noncyclam Small-Molecule CXC Chemokine Receptor 4 Inhibitors , 2008, Molecular Pharmacology.

[4]  Krzysztof Palczewski,et al.  Crystal structure of a photoactivated deprotonated intermediate of rhodopsin , 2006, Proceedings of the National Academy of Sciences.

[5]  T. Blundell,et al.  Comparative protein modelling by satisfaction of spatial restraints. , 1993, Journal of molecular biology.

[6]  Ajay N. Jain Surflex-Dock 2.1: Robust performance from ligand energetic modeling, ring flexibility, and knowledge-based search , 2007, J. Comput. Aided Mol. Des..

[7]  Arthur Christopoulos,et al.  A Novel Mechanism of G Protein-coupled Receptor Functional Selectivity , 2008, Journal of Biological Chemistry.

[8]  A. Smolyar,et al.  Static and dynamic roles of extracellular loops in G-protein-coupled receptors: a mechanism for sequential binding of thyrotropin-releasing hormone to its receptor. , 1998, Biophysical journal.

[9]  Patrick Scheerer,et al.  Crystal structure of the ligand-free G-protein-coupled receptor opsin , 2008, Nature.

[10]  P. Malherbe,et al.  Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. , 2003, Molecular pharmacology.

[11]  D. Rognan,et al.  Protein-based virtual screening of chemical databases. 1. Evaluation of different docking/scoring combinations. , 2000, Journal of medicinal chemistry.

[12]  R. Stevens,et al.  The 2.6 Angstrom Crystal Structure of a Human A2A Adenosine Receptor Bound to an Antagonist , 2008, Science.

[13]  Stefano Costanzi,et al.  On the applicability of GPCR homology models to computer-aided drug discovery: a comparison between in silico and crystal structures of the beta2-adrenergic receptor. , 2008, Journal of medicinal chemistry.

[14]  H. Kikkawa,et al.  The role of the seventh transmembrane region in high affinity binding of a beta 2-selective agonist TA-2005. , 1998, Molecular pharmacology.

[15]  D. Robertson,et al.  Corticotropin releasing factor (CRF) receptor modulators: progress and opportunities for new therapeutic agents. , 2000, Journal of medicinal chemistry.

[16]  Rolf Apweiler,et al.  Evaluation of methods for the prediction of membrane spanning regions , 2001, Bioinform..

[17]  Andreas Evers,et al.  Virtual screening of biogenic amine-binding G-protein coupled receptors: comparative evaluation of protein- and ligand-based virtual screening protocols. , 2005, Journal of medicinal chemistry.

[18]  Yu Zhang,et al.  Discovery of a Novel CCR5 Antagonist Lead Compound Through Fragment Assembly , 2008, Molecules.

[19]  Antti Poso,et al.  Virtual screening of novel CB2 ligands using a comparative model of the human cannabinoid CB2 receptor. , 2005, Journal of medicinal chemistry.

[20]  T. Klabunde,et al.  Structure-based drug discovery using GPCR homology modeling: successful virtual screening for antagonists of the alpha1A adrenergic receptor. , 2005, Journal of medicinal chemistry.

[21]  Olga Yuzlenko,et al.  Molecular modeling of A1 and A2A adenosine receptors: Comparison of rhodopsin‐ and β2‐adrenergic‐based homology models through the docking studies , 2009, J. Comput. Chem..

[22]  R. Stevens,et al.  High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. , 2007, Science.

[23]  Sid Topiol,et al.  Use of the X-ray structure of the Beta2-adrenergic receptor for drug discovery. , 2008, Bioorganic & medicinal chemistry letters.

[24]  M Stahl,et al.  Development of filter functions for protein-ligand docking. , 1998, Journal of molecular graphics & modelling.

[25]  P. Newham,et al.  The orphan G-protein coupled receptor RDC1: evidence for a role in chondrocyte hypertrophy and articular cartilage matrix turnover. , 2006, Osteoarthritis and cartilage.

[26]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[27]  B. Kobilka Agonist binding: a multistep process. , 2004, Molecular pharmacology.

[28]  Fred E. Cohen,et al.  Automated extraction of mutation data from the literature: application of MuteXt to G protein-coupled receptors and nuclear hormone receptors , 2004, Bioinform..

[29]  Axel L. Dessal,et al.  G protein betagamma subunits as targets for small molecule therapeutic development. , 2008, Combinatorial chemistry & high throughput screening.

[30]  Chris G. Kruse,et al.  Assessment of scaffold hopping efficiency by use of molecular interaction fingerprints. , 2008, Journal of medicinal chemistry.

[31]  J. Ballesteros,et al.  Beta2 adrenergic receptor activation. Modulation of the proline kink in transmembrane 6 by a rotamer toggle switch. , 2002, The Journal of biological chemistry.

[32]  Delineation of Agonist Binding to the Human Histamine H4 Receptor Using Mutational Analysis, Homology Modeling, and ab initio Calculations. , 2008 .

[33]  Thomas Lengauer,et al.  Flexible docking under pharmacophore type constraints , 2002, J. Comput. Aided Mol. Des..

[34]  I. Muegge Selection criteria for drug‐like compounds , 2003, Medicinal research reviews (Print).

[35]  J. Vilardaga,et al.  Role of charged amino acids conserved in the vasoactive intestinal polypeptide/secretin family of receptors on the secretin receptor functionality☆ , 1999, Peptides.

[36]  K. Jacobson,et al.  Mutagenesis reveals structure-activity parallels between human A2A adenosine receptors and biogenic amine G protein-coupled receptors. , 1997, Journal of medicinal chemistry.

[37]  D. Hay,et al.  A key role for transmembrane prolines in calcitonin receptor-like receptor agonist binding and signalling: implications for family B G-protein-coupled receptors. , 2005, Molecular pharmacology.

[38]  K. Adachi,et al.  Asymmetric synthesis and biological evaluation of the enantiomeric isomers of the immunosuppressive FTY720-phosphate. , 2005, Bioorganic & medicinal chemistry.

[39]  Didier Rognan,et al.  Protein‐based virtual screening of chemical databases. II. Are homology models of g‐protein coupled receptors suitable targets? , 2002, Proteins.

[40]  D. Grigoriadis,et al.  Corrigendum to “1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: Novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF1) receptor antagonist activities” [Bioorg. Med. Chem. Lett. 11 (2001) 3165–3168] , 2010 .

[41]  Krzysztof Palczewski,et al.  Sequence analyses of G-protein-coupled receptors: similarities to rhodopsin. , 2003, Biochemistry.

[42]  Andreas Mühlemann,et al.  Determination of key amino acids implicated in the actions of allosteric modulation by 3,3'-difluorobenzaldazine on rat mGlu5 receptors. , 2006, European journal of pharmacology.

[43]  Duan Yang,et al.  The evolution of transmembrane helix kinks and the structural diversity of G protein-coupled receptors. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Didier Rognan,et al.  A chemogenomic analysis of the transmembrane binding cavity of human G‐protein‐coupled receptors , 2005, Proteins.

[45]  Jun Zhang,et al.  Molecular Interactions of CCR5 with Major Classes of Small-Molecule Anti-HIV CCR5 Antagonists , 2008, Molecular Pharmacology.

[46]  H. Khorana,et al.  Requirement of Rigid-Body Motion of Transmembrane Helices for Light Activation of Rhodopsin , 1996, Science.

[47]  Z. Deng,et al.  Structural interaction fingerprint (SIFt): a novel method for analyzing three-dimensional protein-ligand binding interactions. , 2004, Journal of medicinal chemistry.

[48]  Pedro Alexandrino Fernandes,et al.  Protein–ligand docking: Current status and future challenges , 2006, Proteins.

[49]  Thomas Lengauer,et al.  Evaluation of the FLEXX incremental construction algorithm for protein–ligand docking , 1999, Proteins.

[50]  C. Hodge,et al.  Corticotropin-releasing hormone receptor antagonists: framework design and synthesis guided by ligand conformational studies. , 1999, Journal of medicinal chemistry.

[51]  Martin Stahl,et al.  Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP , 2006, Journal of neurochemistry.

[52]  S. Betz,et al.  Single amino acid residue determinants of non-peptide antagonist binding to the corticotropin-releasing factor1 (CRF1) receptor. , 2006, Biochemical pharmacology.

[53]  K. Palczewski,et al.  Crystal Structure of Rhodopsin: A G‐Protein‐Coupled Receptor , 2000, Science.

[54]  Leonardo Pardo,et al.  Structural models of class a G protein-coupled receptors as a tool for drug design: insights on transmembrane bundle plasticity. , 2007, Current topics in medicinal chemistry.

[55]  J. Ballesteros,et al.  Structural mimicry in G protein-coupled receptors: implications of the high-resolution structure of rhodopsin for structure-function analysis of rhodopsin-like receptors. , 2001, Molecular pharmacology.

[56]  Peter L. Freddolino,et al.  Predicted 3D structure for the human beta 2 adrenergic receptor and its binding site for agonists and antagonists. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[57]  A. IJzerman,et al.  Involvement of Asn-293 in stereospecific agonist recognition and in activation of the beta 2-adrenergic receptor. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[58]  Y. Fujiwara,et al.  Identification of the Hydrophobic Ligand Binding Pocket of the S1P1 Receptor* , 2007, Journal of Biological Chemistry.

[59]  O. Lichtarge,et al.  Similar structures and shared switch mechanisms of the beta2-adrenoceptor and the parathyroid hormone receptor. Zn(II) bridges between helices III and VI block activation. , 1999, The Journal of biological chemistry.

[60]  Didier Rognan,et al.  Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..

[61]  J. Ballesteros,et al.  The Forgotten Serine , 2000, The Journal of Biological Chemistry.

[62]  E. Kellenberger,et al.  Identification of nonpeptide CCR5 receptor agonists by structure-based virtual screening. , 2007, Journal of medicinal chemistry.

[63]  F. Gasparini,et al.  The Non-competitive Antagonists 2-Methyl-6-(phenylethynyl)pyridine and 7-Hydroxyiminocyclopropan[b]chromen-1a-carboxylic Acid Ethyl Ester Interact with Overlapping Binding Pockets in the Transmembrane Region of Group I Metabotropic Glutamate Receptors* , 2000, The Journal of Biological Chemistry.

[64]  Béla Noszál,et al.  Binding mode analysis and enrichment studies on homology models of the human histamine H4 receptor. , 2008, European journal of medicinal chemistry.

[65]  Antti Poso,et al.  Development of a 3D model for the human cannabinoid CB1 receptor. , 2004, Journal of medicinal chemistry.

[66]  J. Wess,et al.  Site-directed Mutagenesis Identifies Residues Involved in Ligand Recognition in the Human A2a Adenosine Receptor (*) , 1995, The Journal of Biological Chemistry.

[67]  D. Rognan,et al.  Modeling and Mutagenesis of the Binding Site of Calhex 231, a Novel Negative Allosteric Modulator of the Extracellular Ca2+-sensing Receptor* , 2003, Journal of Biological Chemistry.

[68]  L. Pardo,et al.  Linking agonist binding to histamine H1 receptor activation , 2005, Nature chemical biology.

[69]  J. Kew,et al.  Mutational Analysis and Molecular Modeling of the Allosteric Binding Site of a Novel, Selective, Noncompetitive Antagonist of the Metabotropic Glutamate 1 Receptor* , 2003, The Journal of Biological Chemistry.

[70]  Shay Bar-Haim,et al.  G protein-coupled receptors: in silico drug discovery in 3D. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[71]  B Fischer,et al.  Receptor flexibility for large-scale in silico ligand screens: chances and challenges. , 2008, Methods in molecular biology.

[72]  J. Jameson,et al.  Absence of constitutively activating mutations in the GHRH receptor in GH-producing pituitary tumors. , 2001, The Journal of clinical endocrinology and metabolism.

[73]  T. Okada,et al.  Local peptide movement in the photoreaction intermediate of rhodopsin , 2006, Proceedings of the National Academy of Sciences.

[74]  S. A. Parent,et al.  Identification of Leu276 of the S1P1 Receptor and Phe263 of the S1P3 Receptor in Interaction with Receptor Specific Agonists by Molecular Modeling, Site-Directed Mutagenesis, and Affinity Studies , 2007, Molecular Pharmacology.

[75]  B. Kobilka,et al.  New G-protein-coupled receptor crystal structures: insights and limitations. , 2008, Trends in pharmacological sciences.

[76]  T. Schwartz,et al.  Molecular Interaction of a Potent Nonpeptide Agonist with the Chemokine Receptor CCR8 , 2007, Molecular Pharmacology.

[77]  Didier Rognan,et al.  Ranking Targets in Structure-Based Virtual Screening of Three-Dimensional Protein Libraries: Methods and Problems , 2008, J. Chem. Inf. Model..

[78]  Christopher A Reynolds,et al.  Toward the active conformations of rhodopsin and the β2‐adrenergic receptor , 2004, Proteins.

[79]  C. Altenbach,et al.  High-resolution distance mapping in rhodopsin reveals the pattern of helix movement due to activation , 2008, Proceedings of the National Academy of Sciences.

[80]  J. Wess,et al.  Glutamate residues in the second extracellular loop of the human A2a adenosine receptor are required for ligand recognition. , 1996, Molecular pharmacology.

[81]  C. Strader,et al.  Identification of two serine residues involved in agonist activation of the beta-adrenergic receptor. , 1989, The Journal of biological chemistry.

[82]  M. Wheeler,et al.  Scanning of the glucagon-like peptide-1 receptor localizes G protein-activating determinants primarily to the N terminus of the third intracellular loop. , 1997, Molecular endocrinology.

[83]  Stefano Costanzi,et al.  A virtual screen for diverse ligands: discovery of selective G protein-coupled receptor antagonists. , 2008, Journal of the American Chemical Society.

[84]  Gebhard F. X. Schertler,et al.  Structure of a β1-adrenergic G-protein-coupled receptor , 2008, Nature.

[85]  G. Klebe,et al.  Ligand-supported homology modelling of protein binding-sites using knowledge-based potentials. , 2003, Journal of molecular biology.

[86]  U. Gether Uncovering molecular mechanisms involved in activation of G protein-coupled receptors. , 2000, Endocrine reviews.

[87]  A. Parrill,et al.  A Single Amino Acid Determines Lysophospholipid Specificity of the S1P1 (EDG1) and LPA1 (EDG2) Phospholipid Growth Factor Receptors* , 2001, The Journal of Biological Chemistry.

[88]  Gert Vriend,et al.  GPCRDB information system for G protein-coupled receptors , 2003, Nucleic Acids Res..

[89]  J. Ballesteros,et al.  [19] Integrated methods for the construction of three-dimensional models and computational probing of structure-function relations in G protein-coupled receptors , 1995 .

[90]  Sebastian Radestock,et al.  Homology Model-Based Virtual Screening for GPCR Ligands Using Docking and Target-Biased Scoring , 2008, J. Chem. Inf. Model..

[91]  G Vriend,et al.  Modeling GPCRs. , 2006, Ernst Schering Foundation symposium proceedings.

[92]  E. Jaeger,et al.  Comparison of automated docking programs as virtual screening tools. , 2005, Journal of Medicinal Chemistry.

[93]  M. Fan,et al.  Transmembrane Residues of the Parathyroid Hormone (PTH)/PTH-related Peptide Receptor That Specifically Affect Binding and Signaling by Agonist Ligands* , 1996, The Journal of Biological Chemistry.

[94]  J. Wess,et al.  Hydrophilic side chains in the third and seventh transmembrane helical domains of human A2A adenosine receptors are required for ligand recognition. , 1996, Molecular pharmacology.

[95]  Stefano Costanzi,et al.  Discovery of novel agonists and antagonists of the free fatty acid receptor 1 (FFAR1) using virtual screening. , 2008, Journal of medicinal chemistry.

[96]  D. E. Clark,et al.  A virtual screening approach to finding novel and potent antagonists at the melanin-concentrating hormone 1 receptor. , 2004, Journal of medicinal chemistry.

[97]  Nagarajan Vaidehi,et al.  Ligand-stabilized conformational states of human beta(2) adrenergic receptor: insight into G-protein-coupled receptor activation. , 2008, Biophysical journal.

[98]  A. Parrill Lysophospholipid interactions with protein targets. , 2008, Biochimica et biophysica acta.

[99]  Didier Rognan,et al.  High‐Throughput Modeling of Human G‐Protein Coupled Receptors: Amino Acid Sequence Alignment, Three‐Dimensional Model Building, and Receptor Library Screening. , 2004 .

[100]  D. Flower,et al.  In silico identified CCR4 antagonists target regulatory T cells and exert adjuvant activity in vaccination , 2008, Proceedings of the National Academy of Sciences.

[101]  T. Frimurer,et al.  Structure of the integral membrane domain of the GLP1 receptor , 1999, Proteins.

[102]  M. Greenwood,et al.  Physiological relevance of GPCR oligomerization and its impact on drug discovery. , 2008, Drug discovery today.

[103]  Garland R Marshall,et al.  Modulating G-protein coupled receptor/G-protein signal transduction by small molecules suggested by virtual screening. , 2008, Journal of medicinal chemistry.

[104]  Junmei Wang,et al.  GPCR Structure-Based Virtual Screening Approach for CB2 Antagonist Search , 2007, J. Chem. Inf. Model..

[105]  Mayako Michino,et al.  Improved model building and assessment of the Calcium‐sensing receptor transmembrane domain , 2008, Proteins.

[106]  Thomas Lengauer Bioinformatics - From Genomes to Therapies - Introduction , 2007 .

[107]  G. Vigers,et al.  Multiple active site corrections for docking and virtual screening. , 2004, Journal of medicinal chemistry.

[108]  Claudio N. Cavasotto,et al.  Discovery of novel chemotypes to a G-protein-coupled receptor through ligand-steered homology modeling and structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[109]  Jürgen Bajorath,et al.  Virtual screening methods that complement HTS. , 2004, Combinatorial chemistry & high throughput screening.

[110]  Béla Noszál,et al.  Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening. , 2008, Journal of medicinal chemistry.

[111]  Thierry Langer,et al.  Pharmacophores and Pharmacophore Searches: LANGER: PHARMACOPHORES AND PHARMACOPHORE SEARCHES O-BK , 2006 .

[112]  Gilles Marcou,et al.  Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm): A Knowledge-Based Approach to Identify Ligand-Anchoring Atoms in Protein Cavities and Prioritize Structure-Based Pharmacophores , 2008, J. Chem. Inf. Model..

[113]  T. Schwartz,et al.  Molecular mechanism of 7TM receptor activation--a global toggle switch model. , 2006, Annual review of pharmacology and toxicology.

[114]  Kenneth Jones,et al.  Use of the X-ray structure of the beta2-adrenergic receptor for drug discovery. Part 2: Identification of active compounds. , 2008, Bioorganic & medicinal chemistry letters.

[115]  C. Strader,et al.  Identification of residues required for ligand binding to the beta-adrenergic receptor. , 1987, Proceedings of the National Academy of Sciences of the United States of America.

[116]  Localization of agonist- and antagonist-binding domains of human corticotropin-releasing factor receptors. , 1997, Molecular endocrinology.

[117]  Shoshana J. Wodak,et al.  Activation of CCR5 by Chemokines Involves an Aromatic Cluster between Transmembrane Helices 2 and 3* , 2003, The Journal of Biological Chemistry.

[118]  Raphael Nudelman,et al.  An integrated in silico 3D model-driven discovery of a novel, potent, and selective amidosulfonamide 5-HT1A agonist (PRX-00023) for the treatment of anxiety and depression. , 2006, Journal of medicinal chemistry.

[119]  Robert P Bywater,et al.  Recognition of privileged structures by G-protein coupled receptors. , 2004, Journal of medicinal chemistry.

[120]  Oliver P. Ernst,et al.  Crystal structure of opsin in its G-protein-interacting conformation , 2008, Nature.

[121]  B. Kobilka,et al.  Amino acid substitutions at position 312 in the seventh hydrophobic segment of the beta 2-adrenergic receptor modify ligand-binding specificity. , 1993, Molecular pharmacology.

[122]  G. Klebe,et al.  Successful virtual screening for a submicromolar antagonist of the neurokinin-1 receptor based on a ligand-supported homology model. , 2004, Journal of medicinal chemistry.

[123]  Didier Rognan,et al.  Assessing the Scaffold Diversity of Screening Libraries , 2006, J. Chem. Inf. Model..

[124]  Richard D. Taylor,et al.  Virtual Screening Using Protein—Ligand Docking: Avoiding Artificial Enrichment. , 2004 .

[125]  D. Langley,et al.  Expanding GPCR homology model binding sites via a balloon potential: A molecular dynamics refinement approach , 2008, Proteins.

[126]  Kurt Kristiansen,et al.  Molecular mechanisms of ligand binding, signaling, and regulation within the superfamily of G-protein-coupled receptors: molecular modeling and mutagenesis approaches to receptor structure and function. , 2004, Pharmacology & therapeutics.

[127]  C. E. Peishoff,et al.  A critical assessment of docking programs and scoring functions. , 2006, Journal of medicinal chemistry.

[128]  Julian Tirado-Rives,et al.  Contribution of conformer focusing to the uncertainty in predicting free energies for protein-ligand binding. , 2006, Journal of medicinal chemistry.

[129]  T. A. Norris,et al.  Molecular Modeling: Basic Principles and Applications H.-D. Höltje and G. Folkers pp. XII + 194, ISBN 3-527-29384-1 , 1999 .

[130]  Ola Engkvist,et al.  Molecular modeling of the second extracellular loop of G‐protein coupled receptors and its implication on structure‐based virtual screening , 2008, Proteins.

[131]  David E. Gloriam,et al.  Comprehensive repertoire and phylogenetic analysis of the G protein-coupled receptors in human and mouse. , 2006, Genomics.

[132]  Didier Rognan,et al.  ConsDock: A new program for the consensus analysis of protein–ligand interactions , 2002, Proteins.

[133]  Leonardo Pardo,et al.  An Activation Switch in the Rhodopsin Family of G Protein-coupled Receptors , 2005, Journal of Biological Chemistry.

[134]  Xueliang Fang,et al.  Molecular modeling of the three-dimensional structure of dopamine 3 (D3) subtype receptor: discovery of novel and potent D3 ligands through a hybrid pharmacophore- and structure-based database searching approach. , 2003, Journal of medicinal chemistry.

[135]  Vadim Cherezov,et al.  A specific cholesterol binding site is established by the 2.8 A structure of the human beta2-adrenergic receptor. , 2008, Structure.

[136]  Tsutomu Kouyama,et al.  Crystal structure of squid rhodopsin , 2008, Nature.

[137]  R. J. Bailey,et al.  Agonist‐dependent consequences of proline to alanine substitution in the transmembrane helices of the calcitonin receptor , 2007, British journal of pharmacology.

[138]  D. Hurst,et al.  Cysteine 2.59(89) in the Second Transmembrane Domain of Human CB2 Receptor Is Accessible within the Ligand Binding Crevice: Evidence for Possible CB2 Deviation from a Rhodopsin Template , 2005, Molecular Pharmacology.

[139]  Gilles Marcou,et al.  Optimizing Fragment and Scaffold Docking by Use of Molecular Interaction Fingerprints , 2007, J. Chem. Inf. Model..

[140]  Gilles Labesse,et al.  Common Structural Requirements for Heptahelical Domain Function in Class A and Class C G Protein-coupled Receptors* , 2007, Journal of Biological Chemistry.

[141]  L. Pardo,et al.  Design, synthesis and pharmacological evaluation of 5-hydroxytryptamine(1a) receptor ligands to explore the three-dimensional structure of the receptor. , 2002, Molecular pharmacology.

[142]  F. Lombardo,et al.  Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. , 2001, Advanced drug delivery reviews.

[143]  T K Attwood,et al.  A compendium of specific motifs for diagnosing GPCR subtypes. , 2001, Trends in pharmacological sciences.

[144]  Maya Topf,et al.  PREDICT modeling and in‐silico screening for G‐protein coupled receptors , 2004, Proteins.

[145]  H. Schiöth,et al.  The G-protein-coupled receptors in the human genome form five main families. Phylogenetic analysis, paralogon groups, and fingerprints. , 2003, Molecular pharmacology.

[146]  Manfred Burghammer,et al.  Structure of bovine rhodopsin in a trigonal crystal form. , 2003, Journal of molecular biology.

[147]  D. Grigoriadis,et al.  1-Alkyl-3-amino-5-aryl-1H-[1,2,4]triazoles: novel synthesis via cyclization of N-acyl-S-methylisothioureas with alkylhydrazines and their potent corticotropin-releasing factor-1 (CRF(1)) receptor antagonist activities. , 2001, Bioorganic & medicinal chemistry letters.

[148]  J. Ballesteros,et al.  Activation of the β2-Adrenergic Receptor Involves Disruption of an Ionic Lock between the Cytoplasmic Ends of Transmembrane Segments 3 and 6* , 2001, The Journal of Biological Chemistry.

[149]  Gerhard Hessler,et al.  Drug Design Strategies for Targeting G‐Protein‐Coupled Receptors , 2002, Chembiochem : a European journal of chemical biology.

[150]  Marcus Elstner,et al.  The retinal conformation and its environment in rhodopsin in light of a new 2.2 A crystal structure. , 2004, Journal of molecular biology.

[151]  O. Civelli,et al.  Orphan GPCR research , 2008, British journal of pharmacology.

[152]  C. Strader,et al.  Conserved aspartic acid residues 79 and 113 of the beta-adrenergic receptor have different roles in receptor function. , 1988, The Journal of biological chemistry.

[153]  Tudor I. Oprea,et al.  Integration of Virtual Screening with High-Throughput Flow Cytometry to Identify Novel Small Molecule Formylpeptide Receptor Antagonistss⃞ , 2005, Molecular Pharmacology.

[154]  Christopher R. Corbeil,et al.  Towards the development of universal, fast and highly accurate docking/scoring methods: a long way to go , 2008, British journal of pharmacology.

[155]  Brian Hudson,et al.  Strategic Pooling of Compounds for High-Throughput Screening , 1999, J. Chem. Inf. Comput. Sci..

[156]  Didier Rognan,et al.  Comparative evaluation of eight docking tools for docking and virtual screening accuracy , 2004, Proteins.

[157]  W. Spooren,et al.  Rational design, synthesis, and structure-activity relationship of benzoxazolones: new potent mglu5 receptor antagonists based on the fenobam structure. , 2007, Bioorganic & medicinal chemistry letters.

[158]  B. Raaka,et al.  Bidirectional, iterative approach to the structural delineation of the functional "chemoprint" in GPR40 for agonist recognition. , 2007, Journal of medicinal chemistry.